Jonathan S. Berek
Key Documents
Contact Information
-
Clinical Offices
Stanford Women's Cancer Center 900 Blake Wilbur Dr, 1st Floor Palo Alto, CA 94304 Tel Work (650) 498-6004 Fax (650) 498-7237Practices at Stanford Hospital and Clinics and Lucile Packard Children's Hospital
- Academic Offices
Personal Information Email Tel (650) 723-5533Alternate Contact Kerry Garcia Assistant to the Chair Email Tel Work 650-723-5533Not for medical emergencies or patient use
Professional Overview
Clinical Focus
- Cancer> Gynecologic Cancer
- Gynecologic Oncology
- Gynecologic Cancers - Gynecologic Oncology
- Ovarian Cancer
- Uterine Cancer
Administrative Appointments
- Chair, Department of Obstetrics and Gynecology, Stanford University School of Medicine (2005 - present)
- Director, Women's Cancer Center, Stanford Cancer Center (2008 - present)
Professional Education
| Fellowship: | UCLA - School of Medicine CA (1981) |
| Residency: | Harvard Medical School, Brigham & Women's Hospital MA (1979) |
| Internship: | Harvard Medical School, Brigham & Women's Hospital MA (1976) |
| Medical Education: | Johns Hopkins University School of Medicine MD (1975) |
| Biomedical Sciences: | Brown University, MMS (1973) |
Scientific Focus
Clinical Trials
- Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Recruiting
- OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission Recruiting
- Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Recruiting
- Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine Carcinosarcoma Recruiting
- Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Recruiting
Publications
- Current management of vulvar cancer. Hematol Oncol Clin North Am. 2012; (1): 45-62
- Personalizing CA125 levels for ovarian cancer screening. Cancer Prev Res (Phila). 2011; (9): 1356-9
- Prophylactic and Risk-Reducing Bilateral Salpingo-oophorectomy: Recommendations Based on Risk of Ovarian Cancer. Obstet Gynecol. 2011; (2 Pt 1): 404
- Prophylactic and risk-reducing bilateral salpingo-oophorectomy: recommendations based on risk of ovarian cancer. Obstet Gynecol. 2010; (3): 733-43
- Strategies and goals: the future of the International Gynecologic Cancer Society: IGCS Presidential Address. Int J Gynecol Cancer. 2010; (9): 1434-9
Help
Trial Administration